CAMBRIDGE, Mass.– Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODY immunotherapies for solid tumors, has appointed Han Myint, M.D., FACP, as Chief Medical Officer.
Dr. Myint will oversee the clinical strategy and execution of Vicero’s expanding portfolio of multi-specific VINCOBODIES, modular antibody fragments that combine multiple mechanisms of action into a single medicine. His immediate focus will be advancing VCR-036, a bispecific PD-1 + CTLA-4 program, into clinical trials. The goal is to demonstrate combination efficacy with a broader therapeutic window by reducing immune-related toxicities that often lead to early treatment discontinuation.
Dr. Myint is a globally recognized hematologist-oncologist with more than three decades of experience across academia, biotech and pharmaceutical industries. He has played key roles in the development, approval and launch of therapies for solid tumors, hematologic malignancies and cellular immunotherapies.
Most recently, he served as Chief Medical Officer at NextCure and NexImmune, guiding first-in-human and proof-of-concept oncology trials. At Celgene, later Bristol Myers Squibb, he was Global Myeloid Disease Lead and Co-Chair of the Global Myeloid Franchise Team, helping drive the approval of multiple breakthrough therapies. Earlier in his career, he held academic leadership positions including Professor of Medicine and Director of the Stem Cell Transplantation and Hematological Malignancies Program at the University of Colorado, Denver.
“Han’s scientific vision and proven leadership in global drug development make him an ideal addition to Vicero as we advance our pipeline,” said Vikram Kansra, Ph.D., Founder and Chief Executive Officer of Vicero. “His experience designing pivotal trials, navigating regulatory pathways and bringing transformative medicines to patients worldwide will be invaluable as we prepare to move our lead program, VCR-036, into the clinic.”
Dr. Myint said he is eager to contribute to Vicero’s mission. “I am excited to join Vicero at this pivotal stage. The company’s focus on enabling safer, more effective immunotherapy combinations addresses one of the most pressing challenges in cancer treatment today. I look forward to partnering with Vicero’s accomplished team, whose expertise and achievements have driven remarkable progress, as we advance our innovative pipeline and bring new hope to patients.”
